Inclusion Criteria:  Patients with complete surgical resection of histologically confirmed AJCC (8th edition) clinical stage III (stage IIIA [lymph node > 1mm],, IIIB, IIIC, IIID) melanoma, in whom a decision for adjuvant treatment with dabrafenib and trametinib has been made before entering the study; V600E mutation-positive cutaneous melanoma; ≥ 18 years of age; Written informed consent signed.  Exclusion Criteria:  Lack of basic demographic and staging data. Current active participation in an interventional clinical trial for treatment of melanoma. Pregnancy or breastfeeding women. Current primary diagnosis of a cancer other than melanoma, that requires systemic or other treatment.